Download PDF
Horm Metab Res 2016; 48(10): 644-652
DOI: 10.1055/s-0042-108730
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis

X.-l. Du   *
1   Nursing Management Department, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
,
W.-x. Jiang   *
2   Department of Otorhinolaryngology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
,
Z.-t. Lv
3   Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
› Author Affiliations
Further Information

Publication History

received 19 March 2016

accepted 04 May 2016

Publication Date:
14 June 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Studies measuring circulating irisin levels in patients with insulin resistance conditions such as type 2 diabetes mellitus (T2DM) and gestational diabetes mellitus (GDM) have achieved controversial results. Our systematic review and meta-analysis aim to assess the circulating irisin levels in patients with diabetes mellitus. Pubmed, EMBASE, CENTRAL, ISI Web of Science, and CNKI were searched to identify observational studies of circulating irisin levels in patients with diabetes mellitus. Two reviewers independently searched the databases and screened studies according to the inclusion criteria. Data were extracted using a standardized collection form. Meta-analysis was performed. A total of 23 studies (17 cross-sectional and 6 case control) involving 1 745 diabetic patients and 1 337 non-diabetic controls were selected. Compared with non-diabetic controls, circulating irisin concentrations were significantly lower in patients with T2DM (SMD −1.72, 95%CI −2.49, −0.96; p<0.00001) and GDM (SMD −0.76, 95CI −1.31, −0.22; p=0.006), but 30 percent higher in patients with T1DM. Circulating irisin in Asian diabetic patients decreased more than European patients. The findings of our current review suggest that circulating irisin levels were decreased in patients with T2DM and GDM, but not in patients with T1DM.

Key words

irisin - type 2 diabetes mellitus - gestational diabetes mellitus - systematic review

* Xing-li Du and Wen-xiu Jiang contributed equally to this work.


 

  • References

  • 1 Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Bostrom EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Hojlund K, Gygi SP, Spiegelman BM. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463-468
    CrossrefPubMedGoogle Scholar
  • 2 Sanchis-Gomar F, Perez-Quilis C. The p38-PGC-1alpha-irisin-betatrophin axis: Exploring new pathways in insulin resistance. Adipocyte 2014; 3: 67-68
    CrossrefPubMedGoogle Scholar
  • 3 Bartelt A, Heeren J. Adipose tissue browning and metabolic health. Nat Rev Endocrinol 2014; 10: 24-36
    PubMedGoogle Scholar
  • 4 Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev 2004; 84: 277-359
    CrossrefPubMedGoogle Scholar
  • 5 Simon D. Epidemiological features of type 2 diabetes. Rev Praticien 2010; 60: 469-473
    PubMedGoogle Scholar
  • 6 Karagiannis T, Bekiari E, Manolopoulos K, Paletas K, Tsapas A. Gestational diabetes mellitus: why screen and how to diagnose. Hippokratia 2010; 14: 151-154
    PubMedGoogle Scholar
  • 7 Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012
    CrossrefPubMedGoogle Scholar
  • 8 Technology Assessment Program. Agency for Healthcare Research and Quality. Available http://www.ahrq.gov/research/findings/ta/index.html Accessed 1 December, 2015
    PubMed
  • 9 Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp Accessed 1 December, 2015
    PubMedGoogle Scholar
  • 10 Alis R, Sanchis-Gomar F, Pareja-Galeano H, Hernandez-Mijares A, Romagnoli M, Victor VM, Rocha M. Association between irisin and homocysteine in euglycemic and diabetic subjects. Clin Biochem 2014; 47: 333-335
    CrossrefPubMedGoogle Scholar
  • 11 Aydin S, Kuloglu T, Aydin S. Copeptin, adropin and irisin concentrations in breast milk and plasma of healthy women and those with gestational diabetes mellitus. Peptides 2013; 47: 66-70
    CrossrefPubMedGoogle Scholar
  • 12 Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK, Kim JG, Lee IK, Park KG. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 2013; 100: 96-101
    CrossrefPubMedGoogle Scholar
  • 13 Duran ID, Gulcelik NE, Unal M, Topcuoglu C, Sezer S, Tuna MM, Berker D, Guler S. Irisin levels in the progression of diabetes in sedentary women. Clin Biochem 2015; 48: 1268-1272
    CrossrefPubMedGoogle Scholar
  • 14 Ebert T, Stepan H, Schrey S, Kralisch S, Hindricks J, Hopf L, Platz M, Lossner U, Jessnitzer B, Drewlo S, Bluher M, Stumvoll M, Fasshauer M. Serum levels of irisin in gestational diabetes mellitus during pregnancy and after delivery. Cytokine 2014; 65: 153-158
    CrossrefPubMedGoogle Scholar
  • 15 Espes D, Lau J, Carlsson PO. Increased levels of irisin in people with long-standing Type 1 diabetes. Diabetic Med 2015; 32: 1172-1176
    CrossrefPubMedGoogle Scholar
  • 16 He WY, Bai Q, AAA LT, Tang CS, Zhang AH. Irisin levels are associated with urotensin II levels in diabetic patients. J Diabetes Investig 2015; 6: 571-576
    CrossrefPubMedGoogle Scholar
  • 17 Hu W, Wang R, Li J, Zhang J, Wang W. Association of irisin concentrations with the presence of diabetic nephropathy and retinopathy. Ann Clin Biochem 2016; 53: 67-74
    CrossrefPubMedGoogle Scholar
  • 18 Kuzmicki M, Telejko B, Lipinska D, Pliszka J, Szamatowicz M, Wilk J, Zbucka-Kretowska M, Laudanski P, Kretowski A, Gorska M, Szamatowicz J. Serum irisin concentration in women with gestational diabetes. Gynecol Endocrinol 2014; 30: 636-639
    CrossrefPubMedGoogle Scholar
  • 19 Liu JJ, Wong MD, Toy WC, Tan CS, Liu S, Ng XW, Tavintharan S, Sum CF, Lim SC. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complicat 2013; 27: 365-369
    CrossrefPubMedGoogle Scholar
  • 20 Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, Ricart W, Fernandez-Real JM. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013; 98: E769-E778
    CrossrefPubMedGoogle Scholar
  • 21 Piya MK, Harte AL, Sivakumar K, Tripathi G, Voyias PD, James S, Sabico S, Al-Daghri NM, Saravanan P, Barber TM, Kumar S, Vatish M, McTernan PG. The identification of irisin in human cerebrospinal fluid: influence of adiposity, metabolic markers, and gestational diabetes. Am J Physiol Endocrinol Metab 2014; 306: E512-E518
    CrossrefPubMedGoogle Scholar
  • 22 Sanchis-Gomar F, Alis R, Pareja-Galeano H, Sola E, Victor VM, Rocha M, Hernandez-Mijares A, Romagnoli M. Circulating irisin levels are not correlated with BMI, age, and other biological parameters in obese and diabetic patients. Endocrine 2014; 46: 674-677
    CrossrefPubMedGoogle Scholar
  • 23 Tang S, Zhang R, Jiang F, Wang J, Chen M, Peng D, Yan J, Wang S, Bao Y, Hu C, Jia W. Circulating irisin levels are associated with lipid and uric acid metabolism in a Chinese population. Clin Exp Pharmacol Physiol 2015; 42: 896-901
    CrossrefPubMedGoogle Scholar
  • 24 Wang H, Zhang X, Chen W, Huang Q, Chen Q. Relationship between serum irisin levels and urinary albumin excretion in patients with type 2 diabetes. J Diabetes Complicat 2015; 29: 384-389
    CrossrefPubMedGoogle Scholar
  • 25 Wang L, Song J, Wang C, Lin P, Liang K, Sun Y, He T, Li W, Zhao R, Qin J, Lu Y, Liu J, Liu F, Hou X, Chen L. Circulating Levels of Betatrophin and Irisin Are Not Associated with Pancreatic beta-Cell Function in Previously Diagnosed Type 2 Diabetes Mellitus Patients. J Diabetes Res 2016; 2616539
    PubMedGoogle Scholar
  • 26 Wawrusiewicz-Kurylonek N, Telejko B, Kuzmicki M, Sobota A, Lipinska D, Pliszka J, Raczkowska B, Kuc P, Urban R, Szamatowicz J, Kretowski A, Laudanski P, Gorska M. Increased Maternal and Cord Blood Betatrophin in Gestational Diabetes. PloS One 2015; 10: e0131171
    CrossrefPubMedGoogle Scholar
  • 27 Xiang L, Xiang G, Yue L, Zhang J, Zhao L. Circulating irisin levels are positively associated with endothelium-dependent vasodilation in newly diagnosed type 2 diabetic patients without clinical angiopathy. Atherosclerosis 2014; 235: 328-333
    CrossrefPubMedGoogle Scholar
  • 28 Xie X, Gao T, Yang M, Chen P, Jin H, Yang L, Yu X. Associations of betatrophin levels with irisin in Chinese women with normal glucose tolerance. Diabetol Metab Syndr 2015; 7: 26
    CrossrefPubMedGoogle Scholar
  • 29 Yuksel MA, Oncul M, Tuten A, Imamoglu M, Acikgoz AS, Kucur M, Madazli R. Maternal serum and fetal cord blood irisin levels in gestational diabetes mellitus. Diabetes Res Clin Pract 2014; 104: 171-175
    CrossrefPubMedGoogle Scholar
  • 30 Zhang C, Ding Z, Lv G, Li J, Zhou P, Zhang J. Lower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta-analysis. J Diabetes 2016; 8: 56-62
    CrossrefPubMedGoogle Scholar
  • 31 Zhang M, Chen P, Chen S, Sun Q, Zeng QC, Chen JY, Liu YX, Cao XH, Ren M, Wang JK. The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. Eur Rev Med Pharmacol Sci 2014; 18: 1567-1572
    PubMedGoogle Scholar
  • 32 Zhao L, Li J, Li ZL, Yang J, Li ML, Wang GL. Circulating irisin is lower in gestational diabetes mellitus. Endocr J 2015; 62: 921-926
    CrossrefPubMedGoogle Scholar
  • 33 Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, Khunti K. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007; 334: 299
    CrossrefPubMedGoogle Scholar
  • 34 Chen N, Li Q, Liu J, Jia S. Irisin, an exercise-induced myokine as a metabolic regulator: an updated narrative review. Diabetes/Metab Res Rev 2016; 32: 51-59
    CrossrefPubMedGoogle Scholar
  • 35 Park KH, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE, Tsoukas MA, Geladari EV, Huh JY, Dincer F, Davis CR, Crowell JA, Mantzoros CS. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 2013; 98: 4899-4907
    CrossrefPubMedGoogle Scholar
  • 36 Al-Daghri NM, Alkharfy KM, Rahman S, Amer OE, Vinodson B, Sabico S, Piya MK, Harte AL, McTernan PG, Alokail MS, Chrousos GP. Irisin as a predictor of glucose metabolism in children: sexually dimorphic effects. Eur J Clin Invest 2014; 44: 119-124
    CrossrefPubMedGoogle Scholar
  • 37 Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, Mantzoros CS. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism Clin Exp 2012; 61: 1725-1738
    CrossrefPubMedGoogle Scholar
  • 38 Hojlund K, Bostrom P. Irisin in obesity and type 2 diabetes. J Diabetes Complicat 2013; 27: 303-304
    CrossrefPubMedGoogle Scholar
  • 39 Buchanan TA, Xiang A, Kjos SL, Watanabe R. What is gestational diabetes?. Diabetes Care 2007; 30 (Suppl. 02) S105-S111
    CrossrefPubMedGoogle Scholar